MiMedx Reports Q3 2026 Results Amid Medicare Reimbursement Headwinds and Sanara Acquisition
MiMedx (MDXG) reported a significant decline in third-quarter net sales to $62 million, a 45% year-over-year decrease primarily driven by Medicare reimbursement changes affecting the wound care segment. While surgical revenue grew by 9% to $40 million, wound care net sales plummeted 71% due to industry-wide volume reductions and pricing pressures. Despite the top-line contraction, the company showed signs of operational improvement, with GAAP gross margins rising to 80% and Adjusted EBITDA improving sequentially by $10 million following cost restructuring. The company is currently navigating the acquisition of Sanara MedTech, which faces regulatory scrutiny from the FTC, though management expects combined revenue run rates to approach $400 million in the first full year.
Tickers: $MDXG
Topics: Adjusted EBITDA GAAP Net Loss Medicare Reimbursement Net Sales Surgical Revenue Wound Care
Read the full article at Motley Fool
Part of the story CRH Reports Q3 2026 Results Amid Arcosa Acquisition and Impairment Charges (8 articles)